D.B. Root & Company LLC Has $482,000 Holdings in Vertex Pharmaceuticals Incorporated $VRTX

D.B. Root & Company LLC decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,082 shares of the pharmaceutical company’s stock after selling 27 shares during the quarter. D.B. Root & Company LLC’s holdings in Vertex Pharmaceuticals were worth $482,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC increased its holdings in Vertex Pharmaceuticals by 15.0% in the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after purchasing an additional 579 shares during the last quarter. NBC Securities Inc. acquired a new position in Vertex Pharmaceuticals in the first quarter valued at about $167,000. RFG Advisory LLC boosted its position in shares of Vertex Pharmaceuticals by 12.1% during the first quarter. RFG Advisory LLC now owns 757 shares of the pharmaceutical company’s stock worth $367,000 after buying an additional 82 shares during the period. SeaCrest Wealth Management LLC acquired a new position in shares of Vertex Pharmaceuticals during the first quarter worth about $370,000. Finally, Pines Wealth Management LLC acquired a new position in shares of Vertex Pharmaceuticals during the first quarter worth about $205,000. Institutional investors own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on VRTX. Scotiabank reduced their price target on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 5th. UBS Group set a $553.00 target price on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Morgan Stanley set a $439.00 target price on Vertex Pharmaceuticals and gave the stock an “equal weight” rating in a research note on Tuesday, August 5th. Leerink Partnrs raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 25th. Finally, Truist Financial set a $490.00 target price on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $493.81.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at $17,535,600. The trade was a 12.50% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ VRTX opened at $403.30 on Monday. The company has a market capitalization of $103.40 billion, a PE ratio of 28.83 and a beta of 0.43. The stock’s 50 day moving average price is $399.12 and its 200-day moving average price is $442.02. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. The company had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. Vertex Pharmaceuticals’s revenue was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.